Key result
Eicosapentaenoic acid (EPA) attenuated endothelin-1-induced cardiomyocyte hypertrophy, protein synthesis, and expression of hypertrophic markers in vitro.
Why the study?
Does eicosapentaenoic acid prevent endothelin-1-induced cardiomyocyte hypertrophy in vitro?
Does eicosapentaenoic acid prevent endothelin-1-induced cardiomyocyte hypertrophy in vitro?
Eicosapentaenoic acid attenuates endothelin-1-induced cardiomyocyte hypertrophy in vitro, potentially via suppression of JNK and TGF-beta 1 signaling pathways.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for EPA in hypertrophy models; leaves open translation to clinical remodeling prevention.
Shimojo et al. (2006) studied Cardiomyocyte hypertrophy. Eicosapentaenoic acid (EPA) vs. Vehicle only (control) and 0.1 nM ET-1 only was evaluated on Cardiomyocyte surface area, protein synthesis rate, and expression of hypertrophic markers. Eicosapentaenoic acid (EPA) attenuated endothelin-1-induced cardiomyocyte hypertrophy, protein synthesis, and expression of hypertrophic markers in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: